LFG
LGND icon

Larson Financial Group’s Ligand Pharmaceuticals LGND Stock Holding History

Larson Financial Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108K Sell
343
-2
-0.6% -$471 ﹤0.01% 1142
2026
Q1 		$68.9K Buy
345
+296
+604% +$58.6K ﹤0.01% 1176
2025
Q4 		$9.26K Hold
49
– – ﹤0.01% 2156
2025
Q3 		$8.68K Buy
49
+47
+2,350% +$6.99K ﹤0.01% 2092
2025
Q2 		$227 Buy
2
+1
+100% +$107 ﹤0.01% 3038
2025
Q1 		$105 Hold
1
– – ﹤0.01% 2904
2024
Q4 		$107 Hold
1
– – ﹤0.01% 2587
2024
Q3 		$100 Hold
1
– – ﹤0.01% 2537
2024
Q2 		$84 Buy
+1
New +$80 ﹤0.01% 2281
2024
Q1 		– Sell
-20
Closed -$1.43K – 1860
2023
Q4 		$1.43K Buy
+20
New +$1.18K ﹤0.01% 1410

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Larson Financial Group's LGND Position: Q2 2026 in Review

Larson Financial Group reduced its Ligand Pharmaceuticals (LGND) stake by 0.58% in Q2 2026, selling an estimated $471 and leaving 343 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #1142.

Larson Financial Group first reported a position in LGND in Q4 2023 and has held it in 10 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Larson Financial Group held 343 shares of Ligand Pharmaceuticals worth $108K as of Q2 2026.
  • Larson Financial Group sold 2 Ligand Pharmaceuticals shares in Q2 2026, an estimated $471.
  • Ligand Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #1142 holding.
  • Larson Financial Group first reported a position in Ligand Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.